FDA expands approval of Spravato for major depressive disorder patientsJanuary 21, 2025 FDA approves Johnson & Johnson’s Spravato as a standalone therapy, marking a breakthrough for treatment-resistant depression and offering rapid relief to patients with unmet medical needs.
